
Attacks on nursing staff are up 26% since 2017, and many go unreported. Nurse experts outline steps for the bedside and for leaders.

Attacks on nursing staff are up 26% since 2017, and many go unreported. Nurse experts outline steps for the bedside and for leaders.

After a run of 2026 oral SERD approvals, Erica L. Mayer, MD, MPH, discusses ESR1 testing and a possible adjuvant role for giredestrant.

Kelsey Martin, AG-ACNP-BC, AOCNP, says new breast cancer approvals in 2026 are bringing targeted treatments to patients earlier and closer to home.

Lisa Carter-Bawa, PhD, MPH, APRN, describes how AI could flag patients eligible for lung screening and why nurses must stay the human in the loop.

In part 2, Team Draft cofounder Chris Draft explains how nurses can help patients with lung cancer feel seen, not blamed, and why their work matters.

Donna D. Catamero, ANP-BC, OCN, CCRC, says CAR T-cell and bispecific therapies have myeloma teams discussing cure, with nurses on the front line.

An ONS nursing practice leader shares takeaways from EONS19 at ESMO 2026, from workforce sustainability to new therapies and subcutaneous care.

Erica L. Mayer, MD, MPH, explains what the all-oral giredestrant plus everolimus regimen asks of patients and oncology nurses between clinic visits.

Jan Franko, MD, PhD, explains how integrated teams of nurses, nurse practitioners, and navigators help patients get complex cancer care near home.

Former NFL linebacker Chris Draft shares how his late wife's lung cancer launched Team Draft and how nurses help families decode a new diagnosis.

The supplement, sold in Europe as OnLife, was evaluated in the single-arm STEFANO study of 146 patients with paclitaxel- or oxaliplatin-induced CIPN.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.

A 5-decade SEER analysis found 5-year survival in young patients rose from 60% to 90%, yet non-Hispanic Black patients fared worst across cancers.

Nurses earn public trust through quiet acts of compassion, reassurance, and presence — a vital lifeline especially in oncology care.

Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.

Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.

Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.

With 10 years of oncology nursing experience, Lee Grabb highlights how nurse navigation, human connection, and compassion transform holistic cancer care.

Lisa Carter-Bawa, PhD, MPH, APRN, explains how blame keeps patients from lung cancer care and how nurses can counter that stigma in the community.

A study of 6 palliative care programs tied trust, proximity, and real-time communication with oncology teams to higher hospice use.

At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.